US/UK/Canada

Share

Contacts

  • Leo Holmgren

    CEO


    +46 70 049 18 42

    • Links

    Quotes

    Completing the toxicology program with these positive results is a major milestone for Pharmability. The data show that our drug candidate is well tolerated even at high exposure levels and, importantly, that systemic exposure is minimal following cutaneous administration. This strengthens the safety profile of cutaneous TIR-C treatment as we prepare for the Phase Ib study in atopic dermatitis.
    Leo Holmgren, CEO, Pharmability
    We are very pleased to welcome Agneta to Pharmability. Her extensive experience in clinical project management and early-phase development strengthens our capacity as we advance TIR-C into its next stage of development and continue building a strong and experienced project team.
    Leo Holmgren, CEO, Pharmability
    Pharmability marks a new chapter for the company. The name captures our ambition to translate immunological research into new therapies and create value for patients as we enter the next phase.
    Leo Holmgren, CEO, Pharmability
    This publication provides important mechanistic insight into how TIR-01 interacts with early myeloid differentiation and promotes the development of tolerogenic dendritic cells. The data strengthen the scientific rationale behind our immunomodulatory strategy and support the continued advancement of our development program toward clinical studies.
    Leo Holmgren, CEO, TIRmed Pharma
    The collaboration with Bachem is an important milestone in our efforts to advance our candidate drug to the clinic. Through this collaboration, we gain access to world-leading manufacturing expertise and strengthen the foundation for offering patients a more durable treatment option
    Leo Holmgren, CEO, TIRmed Pharma
    The expanded partnership with Zelmic marks a milestone in the clinical development of TIR-C. Zelmic’s deep expertise in topical formulation development strengthens the foundation for our clinical program and supports our mission to improve treatment outcomes for patients with atopic dermatitis worldwide.
    Leo Holmgren, CEO, TIRmed Pharma
    These are the final safety studies before entering the clinic – a critical milestone in our development program. ERBC’s experience with this type of study makes them a valuable partner, and with their support, we are confident in generating the data needed to move into Phase I next year.
    Leo Holmgren, CEO, TIRmed Pharma
    We are very pleased to welcome Peder Walberg and Christian Krog-Jensen to the board. Their complementary expertise in clinical development, strategic planning, and financing will be essential as we bring TIR-C into the clinic and position the company for long-term success
    Leo Holmgren, CEO, TIRmed Pharma
    Bringing TIR-C into the clinic is a major milestone for us – and it demands the right team. Elisabeth brings not only extensive experience, but also the strategic mindset we need at this stage. Her contributions will be essential as we move through the regulatory process and prepare for clinical execution.
    Leo Holmgren, CEO of TIRmed Pharma.
    This capital injection enables us to take the decisive step into clinical development and move closer to a future where patients have access to more durable and effective treatment. The strong support from Sciety and their investor network gives us both the momentum and the means to accelerate our development.
    Leo Holmgren, CEO, TIRmed Pharma
    Pick a time period -
    Tags ( Active)

    Pharmability completes toxicology programme with positive results ahead of Phase Ib study

    Pharmability, a biotechnology company developing next-generation treatments for autoimmune skin diseases, today announced the completion of its GLP toxicology programme for TIR-C, the company’s drug candidate for atopic dermatitis (eczema). Positive results from complementary rat and minipig studies confirm a favourable preclinical safety profile, characterised by low systemic exposure and a clear safety margin, supporting the planned Phase Ib clinical trial.[pharmability-toxicology-program-completed.png] The toxicology programme comprised two studies evaluating systemic and dermal

    Agneta Wennerholm joins Pharmability as Consulting Clinical Project Manager

    Pharmability, a biotechnology company developing next-generation treatments for autoimmune skin diseases, today announced the appointment of Agneta Wennerholm as Clinical Project Manager. The appointment supports the company’s preparations for the clinical development of TIR-C, a novel immunomodulatory drug candidate for the treatment of atopic dermatitis (eczema).[Agneta-Wennerholm-Clinical-Project-Manager-Pharmability-AB.png] Agneta Wennerholm brings more than 25 years of experience in clinical development across pharmaceutical and biotechnology companies and clinical CROs in a broad

    TIRmed Pharma Changes Its Name to Pharmability

    TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, today announced that it has changed its name to Pharmability AB. The name change reflects the company’s development in recent years and marks a new step in its strategic direction.[TIRmed-AB-changes-name-to-Pharmability-AB.png] Over the past few years, the company has evolved from an early-stage research initiative into a biotechnology company focused on translating immunological research into new therapies for patients with autoimmune diseases. This progression has made the need

    TIRmed Pharma Publishes New Mechanistic Findings on TIR-01 in European Journal of Immunology

    TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, announces the publication of new research on its immunomodulatory oligonucleotide TIR-01 in the European Journal of Immunology. The study provides mechanistic insight into how TIR-01 affects human monocyte differentiation and supports the development of tolerogenic dendritic cells—processes that are central to immune regulation in inflammatory skin diseases such as atopic dermatitis (eczema).[TIRmed-Pharma-publishes-new-mechanistic-findings-TIR-01-EJI.png] The work builds on earlier

    TIRmed Enters into Collaboration with Bachem to Advance Oligonucleotide Therapy for Atopic Dermatitis

    TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, has entered into a collaboration with Bachem, a leading company in advanced oligonucleotide manufacturing. The collaboration covers process development and manufacturing of TIR-01, the active pharmaceutical ingredient in TIRmed’s novel therapy for atopic dermatitis (eczema). This marks an important step toward upcoming clinical trials.[TIRmed-Pharma-Bachem-collaboration-oligonucleotide-therapy-atopic-dermatitis.png] TIRmed Pharma is advancing a next-generation treatment for atopic

    TIRmed Pharma Strengthens Partnership with Zelmic Ahead of Clinical Studies in Atopic Dermatitis

    TIRmed Pharma, a biotechnology company developing innovative treatments for autoimmune skin diseases, has expanded its collaboration with Zelmic, a leading specialist in formulation development. The partnership covers GMP development and manufacturing of TIRmed’s topical drug candidate TIR-C for the treatment of atopic dermatitis (eczema), aiming to ensure high product quality ahead of upcoming clinical trials.[TIRmed-Zelmic-Collaboration-Ahead-of-Clinical-Studies-Atopic-Dermatitis.png] TIRmed Pharma is developing a new treatment for atopic dermatitis, with the goal of offering patients

    TIRmed Pharma initiates collaboration with ERBC for regulatory safety studies ahead of its first clinical trial

    TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, has entered into a collaboration with ERBC, a leading European CRO specialized in toxicology studies. The partnership covers two regulatory safety studies, marking the final steps ahead of the company’s planned Phase I clinical trial in 2026.[TIRmed-Pharma-initiates-collaboration-ERBC.jpg] These studies represent the final preclinical steps for TIR-C, TIRmed’s topical drug candidate for the treatment of atopic dermatitis (eczema). The first safety study has already begun, and the

    TIRmed Pharma Appoints Two Experienced Industry Profiles to the Board – Strengthens Readiness for Clinical Phase

    TIRmed Pharma, a biotechnology company developing innovative treatments for autoimmune skin diseases, has appointed Peder Walberg and Christian Krog-Jensen to its Board of Directors. The appointments come at a pivotal stage as the company intensifies preparations for the upcoming Phase Ib clinical trial of its lead drug candidate, TIR-C, targeting atopic dermatitis (eczema). TIRmed is advancing a next-generation treatment for atopic dermatitis, designed to offer patients effective relief with fewer side effects and simpler administration. The treatment targets the root causes of the

    TIRmed Pharma Strengthens Regulatory Expertise Ahead of Clinical Trials

    TIRmed Pharma, a biotechnology company developing innovative treatments for autoimmune skin diseases, has strengthened its regulatory capabilities by recruiting Elisabeth Augustsson, a leading specialist in regulatory affairs. The appointment marks an important step in the preparations for clinical trials of TIR-C, the company’s novel immunomodulatory treatment for atopic dermatitis (eczema).[En bild som visar Människoansikte, person, leende, klädsel AI-genererat innehåll kan vara felaktigt.] Elisabeth Augustsson, a seasoned regulatory affairs expert with extensive experience working with

    TIRmed Pharma raises EUR 4.3 million – preparing for clinical development of new immunomodulatory treatment for atopic dermatitis

    TIRmed Pharma, a biotech company developing innovative treatments for autoimmune skin diseases, has raised EUR 4.3 million in a funding round led by Sciety and Sciety Venture Partners. The investment will support the company’s transition into clinical development of its immunomodulatory treatment for atopic dermatitis – a condition with significant unmet medical need, where more effective therapies with favorable safety profiles are still lacking.[TIRmed Pharma raises EUR 4.3 million.jpg] The EUR 4.3 million raised will enable completion of toxicology studies, GMP production, and

    TIR-01 effect on T-helper cells published in Advanced Science

    We are proud to announce that Advanced Science has published the recent article titled "A Non-Coding Oligonucleotide Recruits Cutaneous CD11b+ Cells that Inhibit T-helper Responses and Promote Tregs." This research unveils the immunoregulatory capabilities of our oligonucleotide TIR-01, highlighting its potential as a therapeutic agent. The study explores how TIR-01 recruits cutaneous immunoregulatory antigen-presenting cells (APCs) that exhibit enhanced expression of immune checkpoint proteins. Through detailed functional T-cell assays, the research demonstrates that these APCs

    TIRmed Pharma consortium receives grant of 1.5 MSEK from Vinnova

    Vinnova, together with Swelife and Medtech4health, have jointly called for new innovative projects within life science and medical technology. The goal is to promote sustainability and innovation, generating value-creating healthcare and increasing growth in the Swedish life science sector. A consortium, led by TIRmed Pharma, have successfully been approved a grant of up to 1.5 MSEK in this programme. TIRmed Pharma, together with Research Institutes of Sweden (RISE) and supported by the patient association Atopikerna (a part of Astma- och Allergiförbundet), have developed a project to

    TIR-C selected for IVA's 100 list

    Prof. Anna-Lena Spetz ‍ TIRmed Pharma's project to developing TIR-C has been listed by Kungliga IngenjörsVetenskapsakademien (IVA) in their annual 100 list as one of the most interesting on-going projects in Sweden. About IVA's 100: IVA 100 highlights a variety of research projects from Swedish universities on the theme of technology in the service of humanity. By building bridges between the research world and the business community, they give research with the potential to change the world a greater opportunity to be turned into actual benefits. Read more about TIRmed Pharma's

    Recruitment of dogs for proof of concept study completed

    We are excited to announce that recruitment of 51 dogs with Atopic Dermatitis for the pivotal proof of concept study has been completed. This is a significant milestone for our company, and we are grateful to everyone who has contributed to this achievement. This study represents a crucial step in our efforts to develop innovative and effective treatments for Atopic Dermatitis, a chronic inflammatory skin condition that affects millions of people worldwide. Treatment of client owned dogs with natural Atopic Dermatitis is considered one the leading translatable models for human Atopic

    Welcome Jianjian and Amirreza - Market intelligence internship

    Amirreza and Jianjian We're excited to introduce our two new interns, Amirreza and Jianjian, who have been driving a market intelligence research project this spring. Amirreza is currently pursuing a Masters degree in Bioentrepreneursip at Karolinska, and brings a strong background in production management, quality management and research & development. He was also an authorized pharmacist. Jianjian is also pursuing a Masters degree in Bioentrepreneursip at Karolinska, with previous experiences as Senior Product Technical Specialist and with a degree in clinical medicine.

    Pirkko Tamsen new member of its Board of Directors

    Pirkko Tamsen, new board member Stockholm, 3 August 2023 - TIRmed Pharma is pleased to announce the appointment of Pirkko Tamsen as a new member of its Board of Directors. This strategic addition to the board further strengthens the company's leadership team and brings valuable expertise to support its growth and strategic objectives. Pirkko Tamsen is a highly accomplished professional with an impressive track record of over 30 years in the pharmaceutical industry. She has held various leadership positions, including CEO of several small pharmaceutical companies and CRO firms, as well

    TIRmed's Recent Dermal Study Yields Promising Results

    In a recent development, TIRmed has conducted a biodistribution study that has yielded very promising results. The study, focused on dermal applications, marks a significant milestone in the company's ongoing research efforts. The primary objective of this study was to assess the potential systemic uptake of TIRmed's product TIR-C, specifically into plasma and, if detectable in plasma, its distribution in vital organs such as the heart, liver, kidney, and spleen. To achieve this, TIRmed initiated a 7-day local tolerability study in minipigs, employing a daily application of the product

    Successful results in subcutaneous repeated dose study in rats

    TIRmed Pharma hasrecently concluded a subcutaneous, non-GLP toxicity study in rats with notablesuccess. The primary goal of this investigation was to assess the occurrence ofside effects at exceptionally high dosage levels. A crucial insight from this studywas that the adverse effects identified align with the well-documented,class-specific side effects associated with oligonucleotides. This findingaffirms the safety profile of our lead candidate TIR-01, mitigating concernsabout unexpected adverse effects. Moreover, this outcome substantially reducesthe risk associated with forthcoming GLP

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media